Home Cart Sign in  
Chemical Structure| 1047953-91-2 Chemical Structure| 1047953-91-2

Structure of MALT1 inhibitor MI-2
CAS No.: 1047953-91-2

Chemical Structure| 1047953-91-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

MI 2 MALT1 inhibitor is a small molecule and irreversible inhibitor of MALT1 with IC50 of 5.84 μM (suppression of proliferation in ABCDLBCL).

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of MALT1 inhibitor MI-2

CAS No. :1047953-91-2
Formula : C19H17Cl3N4O3
M.W : 455.72
SMILES Code : O=C(NC1=CC=C(N2N=C(OCCOC)N=C2C3=CC=C(Cl)C(Cl)=C3)C=C1)CCl
InChI Key :TWJGQZBSEMDPQP-UHFFFAOYSA-N
Pubchem ID :45942672

Safety of MALT1 inhibitor MI-2

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

Description
MI-2, a MALT1 inhibitor (IC50=5.84 μM), directly targets MALT1, irreversibly inhibiting its protease activity. This inhibition is associated with decreased NF-κB reporter activity, blocked c-REL nuclear translocation, and reduced expression of NF-κB-dependent genes. MI-2 is non-toxic to animals[1].

In Vitro:

Cell Line
Concentration Treated Time Description References
monocytes 0.5 μM 12 days MI-2 strongly suppressed the differentiation of monocytes into osteoclasts in the absence or presence of the inflammatory cytokine TNFα. PMC5605699
U87 cells 0, 2, 4 μM 12 hours To evaluate the effect of MI-2 on cell proliferation, the results showed that MI-2 significantly inhibited the proliferation of U87 cells. PMC7339184
U251 cells 0, 2, 4 μM 12 hours To evaluate the effect of MI-2 on cell proliferation, the results showed that MI-2 significantly inhibited the proliferation of U251 cells. PMC7339184
MEC1 cells 0.2 μM 24 hours MI-2 dose-dependently reduced the viability of MEC1 cells with an IC50 of 0.2 μM at 24 hours. PMC5732856
PBMCs from CLL patients 1.17 μM 24 hours MI-2 induced dose-dependent cell death in PBMCs from CLL patients with a mean IC50 of 1.17 μM. PMC5732856
PBMCs from healthy volunteers 10 μM 24 hours MI-2 significantly increased cell death in PBMCs from healthy volunteers at 10 μM concentration. PMC5732856
aortic smooth muscle cells (SMCs) 0.1 μM, 1 μM, 2.5 μM, 5 μM, 10 μM 3 hours, 6 hours, 24 hours MI-2 induced cell death in aortic SMCs, which was rescued by the iron chelator DFO or Fer-1 (a specific inhibitor of ferroptosis), but not by inhibitors of apoptosis, pyroptosis, or necrosis. MI-2 downregulated the expression of GPX4 and FTH1, activated autophagy, and reduced the cleavage of CYLD. PMC10721807
Human myeloma cell lines (RPMI8226, IM9, H929, U266, OPM2, MM1R, MM1S) 1 μM 48 hours To evaluate the effect of MI-2 on the growth of multiple myeloma cells, results showed that MI-2 significantly inhibited cell growth and induced mitochondria-dependent apoptosis PMC11339052
Primary multiple myeloma cells (CD138+) 1.5 μM 48 hours To evaluate the effect of MI-2 on primary multiple myeloma cells, results showed that MI-2 exerted strong cytotoxicity against CD138+ cells PMC11339052
mouse and human aortic SMCs 1 μM 6 hours MI-2 induced ferroptotic cell death in mouse and human aortic SMCs, increased intracellular iron levels, and disrupted mitochondrial structure. PMC10721807
B-ALL cell lines 50 mM 96 hours To evaluate the killing effect of Z-VRPR-fmk on B-ALL cell lines, results showed significant reduction in cell viability PMC11063839

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice C57BL/6 mice intraperitoneal injection 0.05 to 25 mg/kg daily for 10 days To evaluate the toxicity of MI-2 in mice, results showed that MI-2 was not significantly toxic to mice PMC3984478
Meat ducks E. coli infection model Intraperitoneal injection 30 mg/kg Once daily for 14 days To study the effect of MI-2 on bone metabolism in E. coli-infected meat ducks, the results showed that MI-2 treatment significantly reduced the levels of bone resorption markers TRAP and CTx and improved bone quality. PMC9354418
NSG mice Human multiple myeloma xenograft model Intraperitoneal injection 25 mg/kg 5 days per week for 4 weeks To evaluate the efficacy of MI-2 in a multiple myeloma xenograft model, results showed that MI-2 significantly prolonged survival and inhibited tumor growth PMC11339052
Mice Bleomycin-induced pulmonary fibrosis model Intraperitoneal injection 30 mg/kg Once daily for 7 or 21 days MI-2 reduced weight loss and mortality, decreased inflammatory cell infiltration, cytokine overexpression, and tissue injury, and modulated the excessive production of reactive oxygen species and inflammatory mediators induced by bleomycin. Additionally, MI-2 demonstrated anti-fibrotic activity by reducing TGF-β, α-SMA, and TRAF6 expression. PMC7589767
Rats Spinal cord ischemia/reperfusion injury model Intraperitoneal injection 25 mg/kg/day For three consecutive days MI-2 alleviates spinal cord ischemia/reperfusion injury-induced blood-spinal cord barrier destruction and neuroinflammation by suppressing NF-κB-ERS signaling, thereby decreasing neuronal loss and protecting hindlimb motor function. PMC8423190
DBA/1 J mice collagen-induced arthritis model intraperitoneal injection 25 mg/kg once daily for 18 days MI-2 significantly ameliorated pathologic bone erosion and synovitis in the collagen-induced arthritis model. PMC5605699
C57BL/6 mice GBM model Intraperitoneal injection 20 mg/kg, 40 mg/kg Daily until the end of the experiment To evaluate the effect of MI-2 on tumor growth in vivo, the results showed that MI-2 significantly inhibited tumor growth and prolonged the survival of mice. PMC7339184
C57BL/6 mice neointima formation model local application 10 μM 3 weeks MI-2 significantly inhibited neointima formation in the carotid artery, and this effect was partially reversed by co-treatment with Fer-1. PMC10721807
NSG mice T-ALL mouse model intraperitoneal injection 20 mg/kg 5 days per week for 4 weeks MI-2 significantly prolonged the survival of T-ALL mouse model and reduced the leukemic burden. PMC7538650

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.19mL

0.44mL

0.22mL

10.97mL

2.19mL

1.10mL

21.94mL

4.39mL

2.19mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories